Literature DB >> 15367630

Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2.

Michael J Moore1, Tatyana Dorfman, Wenhui Li, Swee Kee Wong, Yanhan Li, Jens H Kuhn, James Coderre, Natalya Vasilieva, Zhongchao Han, Thomas C Greenough, Michael Farzan, Hyeryun Choe.   

Abstract

Infection of receptor-bearing cells by coronaviruses is mediated by their spike (S) proteins. The coronavirus (SARS-CoV) that causes severe acute respiratory syndrome (SARS) infects cells expressing the receptor angiotensin-converting enzyme 2 (ACE2). Here we show that codon optimization of the SARS-CoV S-protein gene substantially enhanced S-protein expression. We also found that two retroviruses, simian immunodeficiency virus (SIV) and murine leukemia virus, both expressing green fluorescent protein and pseudotyped with SARS-CoV S protein or S-protein variants, efficiently infected HEK293T cells stably expressing ACE2. Infection mediated by an S-protein variant whose cytoplasmic domain had been truncated and altered to include a fragment of the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein was, in both cases, substantially more efficient than that mediated by wild-type S protein. Using S-protein-pseudotyped SIV, we found that the enzymatic activity of ACE2 made no contribution to S-protein-mediated infection. Finally, we show that a soluble and catalytically inactive form of ACE2 potently blocked infection by S-protein-pseudotyped retrovirus and by SARS-CoV. These results permit studies of SARS-CoV entry inhibitors without the use of live virus and suggest a candidate therapy for SARS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367630      PMCID: PMC516384          DOI: 10.1128/JVI.78.19.10628-10635.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Characterization of a novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Paul A Rota; M Steven Oberste; Stephan S Monroe; W Allan Nix; Ray Campagnoli; Joseph P Icenogle; Silvia Peñaranda; Bettina Bankamp; Kaija Maher; Min-Hsin Chen; Suxiong Tong; Azaibi Tamin; Luis Lowe; Michael Frace; Joseph L DeRisi; Qi Chen; David Wang; Dean D Erdman; Teresa C T Peret; Cara Burns; Thomas G Ksiazek; Pierre E Rollin; Anthony Sanchez; Stephanie Liffick; Brian Holloway; Josef Limor; Karen McCaustland; Melissa Olsen-Rasmussen; Ron Fouchier; Stephan Günther; Albert D M E Osterhaus; Christian Drosten; Mark A Pallansch; Larry J Anderson; William J Bellini
Journal:  Science       Date:  2003-05-01       Impact factor: 47.728

2.  Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.

Authors:  Natalie A Dales; Alexandra E Gould; James A Brown; Emily F Calderwood; Bing Guan; Charles A Minor; James M Gavin; Paul Hales; Virendar K Kaushik; Michael Stewart; Peter J Tummino; Chad S Vickers; Timothy D Ocain; Michael A Patane
Journal:  J Am Chem Soc       Date:  2002-10-09       Impact factor: 15.419

3.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

4.  Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor.

Authors:  T Mirzabekov; N Bannert; M Farzan; W Hofmann; P Kolchinsky; L Wu; R Wyatt; J Sodroski
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

5.  Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein.

Authors:  K W Chang; Y Sheng; J L Gombold
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

6.  Novel peptide inhibitors of angiotensin-converting enzyme 2.

Authors:  Lili Huang; Daniel J Sexton; Kirsten Skogerson; Mary Devlin; Rodger Smith; Indra Sanyal; Tom Parry; Rachel Kent; Jasmin Enright; Qi-long Wu; Greg Conley; Daniel DeOliveira; Lee Morganelli; Matthew Ducar; Charles R Wescott; Robert C Ladner
Journal:  J Biol Chem       Date:  2003-02-26       Impact factor: 5.157

7.  The Genome sequence of the SARS-associated coronavirus.

Authors:  Marco A Marra; Steven J M Jones; Caroline R Astell; Robert A Holt; Angela Brooks-Wilson; Yaron S N Butterfield; Jaswinder Khattra; Jennifer K Asano; Sarah A Barber; Susanna Y Chan; Alison Cloutier; Shaun M Coughlin; Doug Freeman; Noreen Girn; Obi L Griffith; Stephen R Leach; Michael Mayo; Helen McDonald; Stephen B Montgomery; Pawan K Pandoh; Anca S Petrescu; A Gordon Robertson; Jacqueline E Schein; Asim Siddiqui; Duane E Smailus; Jeff M Stott; George S Yang; Francis Plummer; Anton Andonov; Harvey Artsob; Nathalie Bastien; Kathy Bernard; Timothy F Booth; Donnie Bowness; Martin Czub; Michael Drebot; Lisa Fernando; Ramon Flick; Michael Garbutt; Michael Gray; Allen Grolla; Steven Jones; Heinz Feldmann; Adrienne Meyers; Amin Kabani; Yan Li; Susan Normand; Ute Stroher; Graham A Tipples; Shaun Tyler; Robert Vogrig; Diane Ward; Brynn Watson; Robert C Brunham; Mel Krajden; Martin Petric; Danuta M Skowronski; Chris Upton; Rachel L Roper
Journal:  Science       Date:  2003-05-01       Impact factor: 47.728

8.  A novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

Review 9.  Restriction factors: a defense against retroviral infection.

Authors:  Paul D Bieniasz
Journal:  Trends Microbiol       Date:  2003-06       Impact factor: 17.079

10.  Aetiology: Koch's postulates fulfilled for SARS virus.

Authors:  Ron A M Fouchier; Thijs Kuiken; Martin Schutten; Geert van Amerongen; Gerard J J van Doornum; Bernadette G van den Hoogen; Malik Peiris; Wilina Lim; Klaus Stöhr; Albert D M E Osterhaus
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

View more
  120 in total

1.  Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease.

Authors:  Matthew Frieman; Boyd Yount; Sudhakar Agnihothram; Carly Page; Eric Donaldson; Anjeanette Roberts; Leatrice Vogel; Becky Woodruff; Diana Scorpio; Kanta Subbarao; Ralph S Baric
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions.

Authors:  Wenhui Li; Swee-Kee Wong; Fang Li; Jens H Kuhn; I-Chueh Huang; Hyeryun Choe; Michael Farzan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 3.  The molecular biology of coronaviruses.

Authors:  Paul S Masters
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

4.  Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry.

Authors:  Rene Broer; Bertrand Boson; Willy Spaan; François-Loïc Cosset; Jeroen Corver
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.

Authors:  Jean K Millet; Tiffany Tang; Lakshmi Nathan; Javier A Jaimes; Hung-Lun Hsu; Susan Daniel; Gary R Whittaker
Journal:  J Vis Exp       Date:  2019-03-01       Impact factor: 1.355

6.  Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

Authors:  Yuxian He; Jingjing Li; Susanne Heck; Sara Lustigman; Shibo Jiang
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms.

Authors:  Yanchen Zhou; Kai Lu; Susanne Pfefferle; Stephanie Bertram; Ilona Glowacka; Christian Drosten; Stefan Pöhlmann; Graham Simmons
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

8.  AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension.

Authors:  Jiao Zhang; Jianjie Dong; Marcy Martin; Ming He; Brendan Gongol; Traci L Marin; Lili Chen; Xinxing Shi; Yanjun Yin; Fenqing Shang; Yan Wu; Hsi-Yuan Huang; Jin Zhang; Yu Zhang; Jian Kang; Esteban A Moya; Hsien-Da Huang; Frank L Powell; Zhen Chen; Patricia A Thistlethwaite; Zu-Yi Yuan; John Y-J Shyy
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

9.  Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus.

Authors:  Woan-Eng Chan; Chin-Kai Chuang; Shiou-Hwei Yeh; Mau-Sun Chang; Steve S-L Chen
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus.

Authors:  Masaya Fukushi; Yoshiyuki Yoshinaka; Yusuke Matsuoka; Seisuke Hatakeyama; Yukihito Ishizaka; Teruo Kirikae; Takehiko Sasazuki; Tohru Miyoshi-Akiyama
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.